Core Insights - CROSSJECT's ZENEO® needle-free auto-injector demonstrates comparable injection depth to traditional 30-mm needles and exceeds the length of many existing auto-injectors, indicating strong clinical and commercial potential [2][3][4] Company Overview - CROSSJECT is a specialty pharmaceuticals company focused on developing emergency medications, particularly through its ZENEO® needle-free auto-injector platform [6] - The company is advancing the regulatory development of ZEPIZURE®, an emergency injectable for epilepsy management, supported by a $60 million contract with BARDA [6][7] Product Performance - In a recent MRI study with 50 healthy subjects, the ZENEO® auto-injector achieved a mean injection depth of 34 mm (±7.5 mm) on bare skin and 28 mm (±8.4 mm) through clothing, both within the intended range for intramuscular injections [4] - The ZENEO® device's performance surpasses that of conventional needle-based auto-injectors, which typically have needle lengths between 11 mm and 25 mm, ensuring rapid and complete dose delivery [4][8] Clinical Validation - The study results align with previous clinical findings, confirming that midazolam injected with ZENEO® is bioequivalent to injections using a 30-mm needle [5] - Local reactions to the treatment were transient and well-tolerated, similar to those experienced with traditional intramuscular injections [5]

Core Insights - CROSSJECT is advancing the Emergency Use Authorization (EUA) filing process for ZEPIZURE®, an injectable treatment for epilepsy crises, in collaboration with BARDA [3][5][6] - The company has successfully completed critical aseptic filling steps for ZEPIZURE® and is on track with final assembly and packaging [4][9] - Initial feedback from the FDA is anticipated within one month of the submission, with the final manufacturing data expected to be delivered by June 2025 [5][9] Company Overview - CROSSJECT is a specialty pharmaceuticals company focused on developing emergency medications using its needle-free auto-injector ZENEO® platform [7] - The company has a $60 million contract with BARDA to support the development of ZEPIZURE® [7][8] - Other products in development include solutions for allergic shocks and adrenal insufficiencies, as well as various emergency therapies [7]

Group 1 - The core announcement is that CROSSJECT has made its 2024 annual financial report available to the public and filed it with the French Financial Markets Authority [2][5] - CROSSJECT is a pharmaceutical company specializing in the advanced development and registration of ZEPIZURE®, an emergency solution for managing epilepsy crises [2][3] - The company has secured a $60 million contract from the U.S. Biomedical Advanced Research and Development Authority (BARDA) for the research and development of ZEPIZURE® [3][4] Group 2 - ZEPIZURE® utilizes the award-winning needle-free auto-injector ZENEO®, allowing untrained patients and caregivers to perform intramuscular injections easily and instantly in emergency situations [3] - CROSSJECT is also developing additional products for emergency treatment of allergic shocks, adrenal insufficiencies, opioid overdoses, and asthma attacks [3]